Sulfamethoxazole and Trimethoprim description, usages, side effects, indications, overdosage, supplying and lots more!

Sulfamethoxazole and Trimethoprim

REMEDYREPACK INC.


FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

Rx Only


DESCRIPTION



DESCRIPTION


DESCRIPTION


CLINICAL PHARMACOLOGY


DOSAGE AND ADMINISTRATIONsection). Detectable amounts of sulfamethoxazole and trimethoprim are present in the blood 24 hours after drug administration. During administration of 800 mg sulfamethoxazole and 160 mg trimethoprim b.i.d., the mean steady-state plasma concentration of trimethoprim was 1.72The steady-state mean plasma levels of free and total sulfamethoxazole were 57.4and 68.0respectively. These steady-state levels were achieved after three days of drug administration.1 Excretion of sulfamethoxazole and trimethoprim is primarily by the kidneys through both glomerular filtration and tubular secretion. Urine concentrations of both sulfamethoxazole and trimethoprim are considerably higher than are the concentrations in the blood. The average percentage of the dose recovered in urine from 0 to 72 hours after a single oral dose of sulfamethoxazole and trimethoprim is 84.5% for total sulfonamide and 66.8% for free trimethoprim. Thirty percent of the total sulfonamide is excreted as free sulfamethoxazole, with the remaining as N4-acetylated metabolite.2 When administered together as sulfamethoxazole and trimethoprim, neither sulfamethoxazole nor trimethoprim affects the urinary excretion pattern of the other.

Geriatric Pharmacokinetics

Microbiology

INDICATIONS AND USAGEsection.
Aerobic Gram-Positive Microorganisms:

Aerobic Gram-Negative Microorganisms:









Other Organisms:

Susceptibility Testing Methods



Quality Control





Quality Control


INDICATIONS & USAGE


Urinary Tract Infections

Acute Otitis Media

Acute Exacerbations of Chronic Bronchitis in Adults

Shigellosis

Pneumocystis Carinii Pneumonia

TravelerDiarrhea in Adults

CONTRAINDICATIONS


WARNINGS

FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE, HAVE OCCURRED DUE TO SEVERE REACTIONS, INCLUDING STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, FULMINANT HEPATIC NECROSIS, AGRANULOCYTOSIS, APLASTIC ANEMIA AND OTHER BLOOD DYSCRASIAS.
SULFONAMIDES, INCLUDING SULFONAMIDE-CONTAINING PRODUCTS SUCH AS SULFAMETHOXAZOLE/TRIMETHOPRIM, SHOULD BE DISCONTINUED AT THE FIRST APPEARANCE OF SKIN RASH OR ANY SIGN OF ADVERSE REACTION.In rare instances, a skin rash may be followed by a more severe reaction, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatic necrosis, and serious blood
PRECAUTIONS). Clinical signs, such as rash, sore throat, fever, arthralgia, pallor, purpura or jaundice may be early indications of serious reactions.
Cough, shortness of breath, and pulmonary infiltrates are hypersensitivity reactions of the respiratory tract that have been reported in association with sulfonamide treatment.
Thrombocytopenia





PRECAUTIONS

General
CLINICAL PHARMACOLOGYandDOSAGE AND ADMINISTRATION).




Use in the Treatment of and Prophylaxis for Pneumocystis Carinii Pneumonia in Patients with Acquired Immunodeficiency Syndrome (AIDS)
WARNINGS).


INFORMATION FOR PATIENTS





LABORATORY TESTS


DRUG INTERACTIONS









DRUG & OR LABORATORY TEST INTERACTIONS



CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY




PREGNANCY






CONTRAINDICATIONSsection.

NURSING MOTHERS

CONTRAINDICATIONSsection.

PEDIATRIC USE

INDICATIONSandCONTRAINDICATIONSsections).

GERIATRIC USE


WARNINGSandADVERSE REACTIONSsections), a specific decrease in platelets (with or withoutpurpura), and hyperkalemia are the most frequently reported severe adverse reactions in elderly patients. In those concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. Increased digoxin blood levels can occur with concomitant sulfamethoxazole and trimethoprim therapy, especially in elderly patients. Serum digoxin levels should be monitored. Hematological changes indicative of folic acid deficiency may occur in elderly patients. These effects are reversible by folinic acid therapy. Appropriate dosage adjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize risks of undesired reactions (seeDOSAGE AND ADMINISTRATIONsection). The trimethoprim component of sulfamethoxazole and trimethoprim may cause hyperkalemia when administered to patients with underlying disorders of potassium metabolism, with renal insufficiency, or when given concomitantly with drugs known to induce hyperkalemia, such as angiotensin converting enzyme inhibitors. Close monitoring of serum potassium is warranted in these patients. Discontinuation of sulfamethoxazole and trimethoprim treatment is recommended to help lower potassium serum levels. Sulfamethoxazole and Trimethoprim Double Strength Tablets contain 3.6 mg (0.16 mEq) of sodium per tablet.
CLINICAL PHARMACOLOGY: Geriatric Pharmacokinetics).

ADVERSE REACTIONS

FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE, HAVE OCCURRED DUE TO SEVERE REACTIONS, INCLUDING STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, FULMINANT HEPATIC NECROSIS, AGRANULOCYTOSIS, APLASTIC ANEMIA AND OTHER BLOOD DYSCRASIAS (SEE WARNINGSSECTION).




PRECAUTIONS: Use in the Treatment of and Prophylaxis for Pneumocystis Carinii Pneumonia in Patients with Acquired Immunodeficiency Syndrome (AIDS).




WARNINGS).

Postmarketing Experience



OVERDOSAGE

Acute



Chronic

DOSAGE & ADMINISTRATION

Not recommended for use in pediatric patients less than 2 months of age.
Urinary Tract Infections and Shigellosis in Adults and Pediatric Patients, and Acute Otitis Media in Children




Acute Exacerbations of Chronic Bronchitis in Adults

Pneumocystis Carinii Pneumonia



Prophylaxis





TravelerDiarrhea in Adults

HOW SUPPLIED















STORAGE AND HANDLING



REFERENCES













PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION














PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION


PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION

Sulfamethoxazole and Trimethoprim

SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLET

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:24236-577(NDC:53746-272)
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
SULFAMETHOXAZOLE sulfamethoxazole 800 mg
TRIMETHOPRIM Trimethoprim 160 mg

Inactive Ingredients

Ingredient Name Strength
MAGNESIUM STEARATE
povidone
STARCH, CORN
SODIUM STARCH GLYCOLATE TYPE A POTATO

Product Characteristics

Color Size Imprint Code Shape
white 19 mm IP;272 OVAL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:24236-577-10 6 in 1 BLISTER PACK

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA076899 2012-08-28


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.